Company Overview and News

 
Global Clean Energy ETF (ICLN) Hits New 52-Week High

2018-04-10 zacks
For investors seeking momentum, iShares Global Clean Energy ETF (ICLN - Free Report) is probably on radar now. The fund just hit a 52-week high and is up nearly 17.9% from its 52-week low price of $8.31/share.

 
Half-year Report

2017-08-03 londonstockexchange
The Company’s investment objectives are to achieve a high income and to realise long term growth in the capital value of its portfolio. The Company will seek to achieve these objectives by investing principally in the equity and equity-related securities of companies operating primarily in the energy and water sectors, as well as other infrastructure investments.

 
Final Results

2017-03-13 londonstockexchange
The Company’s investment objectives are to achieve a high income and to realise long term growth in the capital value of its portfolio. The Company will seek to achieve these objectives by investing principally in the equity and equity-related securities of companies operating primarily in the energy and water sectors, as well as other infrastructure investments.

 
Beijing’s power tariff cut proposal hammers Chinese renewable energy stocks

2016-09-30 scmp
Shares of Chinese developers of wind and solar power projects sank after Beijing proposed substantial cuts to their subsidised power tariffs to plug the growing deficit in the state-financed renewable energy subsidy fund.

 
Hong Kong’s Link Reit issues US$500 million green bond

2016-07-15 scmp
Property investment giant Link Reit, which has faced a torrent of criticism from politicians and government officials on its profit-driven practise of pushing up rents and driving out small retailers, is set to become Hong Kong’s first issuer of a so-called green bond to finance projects that help protect the environment.

 
Link Reit set to issue US$500 million green bond

2016-07-14 scmp
Property investment giant Link Reit, which has faced a torrent of criticism from politicians and government officials on its profit-driven practise of pushing up rents and driving out small retailers, is set to become Hong Kong’s first issuer of a so-called green bond to finance projects that help protect the environment.

 
Asia Pacific Market: Stocks up in quite trade, US jobs data eyed for Fed clues

2016-06-03 indiainfoline
We encourage visitors to register on IIFL. Registering on the site is absolutely Free and offers you the following benefits.

 
Hong Kong, Shanghai shares close out trading week on an upbeat note

2016-03-18 scmp
Hong Kong and Chinese mainland stock markets closed out the trading week with solid gains on Friday, lifted by an upbeat investor tone that’s been in place since the Federal Reserve signalled a more dovish outlook on the pace of interest rate hikes, helping send the US dollar lower against its Asian counterparts.

 
Hong Kong, China stocks close morning session higher

2016-03-18 scmp
Hong Kong stocks closed the morning session higher on Friday, with analysts expecting the uptrend to continue as the Hong Kong dollar strengthens.

 
China’s Huaneng Renewables slows down expansion after power price cut

2016-03-17 scmp
Company had 9.72 GW of installed wind farms and 0.63 GW of solar farms at the end of last year

 
China’s wind power sector to see more headwinds

2016-01-27 scmp
Weak power demand and too much capacity expansion in remote regions the main culprits

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...